News
NRXP
2.510
-0.40%
-0.010
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
TipRanks · 6h ago
NRx Pharmaceuticals announces incorporation of NRx Defense Systems
TipRanks · 6h ago
BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financial, Papa John's
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Gitlab, Snap, Robinhood
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, BofA, Snap
Reuters · 1d ago
BUZZ-NRx Pharmaceuticals rises as it launches defense-focused mental health unit
Reuters · 1d ago
NRx advances robotic TMS plus D-cycloserine neuroplastic therapy for military, responders
PUBT · 1d ago
NRX PHARMACEUTICALS INC: DEVELOPMENT INITIATIVE TO BE CONDUCTED THROUGH R&D UNIT NRX DEFENSE SYSTEMS, IN PARTNERSHIP WITH ZETA SURGICAL
Reuters · 1d ago
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
Barchart · 1d ago
NRx Pharmaceuticals appoints Glenn Tyson chief commercial officer
TipRanks · 3d ago
NRx Pharmaceuticals names Glenn Tyson as first chief commercial officer
PUBT · 3d ago
Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer
Dow Jones · 3d ago
Weekly Report: what happened at NRXP last week (0406-0410)?
Weekly Report · 3d ago
Psychedelic: AtaiBeckley reports publication of BPL-003 study results
TipRanks · 04/09 15:00
NRx Pharmaceuticals announces FDA labeling alignment for ketamine product
TipRanks · 04/06 11:18
NRx Pharmaceuticals Receives FDA Letter Regarding Comments On Minor Formatting Changes To Proposed Label For Its Preservative-Free Ketamine Product, The Company Expects To Submit Final Label In April
Benzinga · 04/06 11:05
NRX PHARMACEUTICALS (NASDAQ:NRXP) ANNOUNCES FDA LABELING ALIGNMENT FOR NRX’S PRESERVATIVE-FREE KETAMINE APPLICATION
Reuters · 04/06 11:00
Weekly Report: what happened at NRXP last week (0330-0403)?
Weekly Report · 04/06 10:01
Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
TipRanks · 04/02 13:55
NRx unit Hope Therapeutics partners with Emobot to deploy AI depression monitoring networkwide
Reuters · 03/30 11:07
More
Webull provides a variety of real-time NRXP stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXP
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.